menu
    • menu
    [{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onco360 \/ CTI BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ CTI BioPharma"},{"orgOrder":0,"company":"Onco360","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Myovant Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Myovant Sciences"},{"orgOrder":0,"company":"Onco360","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Servier","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Servier"},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Onco360 \/ Onco360","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Onco360"},{"orgOrder":0,"company":"Onco360","sponsor":"Geron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Imetelstat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Onco360 \/ Geron","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Geron"}]

    Find Clinical Drug Pipeline Developments & Deals by Onco360

    Menu

    Onco360

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imetelstat

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Geron

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Onco360 Chosen as Specialty Pharmacy Partner for Rytelo™ (Imetelstat)

                            Details : Onco360 partner by Geron for the distribution of Rytelo (imetelstat)l, telomerase inhibitor, approved for the treatment of adult patients with low to intermediate-risk myelodysplastic syndromes.

                            Brand Name : Rytelo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 12, 2024

                            Lead Product(s) : Imetelstat

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Geron

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Day One Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BrightSpring Health Announces Onco360 was Selected as National Pharmacy Partner for OJEMDA

                            Details : Onco360 is being selected as a pharmacy partner by Day One Biopharmaceuticals for Ojemda, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.

                            Brand Name : Ojemda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Day One Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lytgobi® (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated...

                            Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR. It has demonstrated anti-tumor activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.

                            Brand Name : Lytgobi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ORSERDU™ Now Available from Onco360 for the Treatment of Postmenopausal Women or Adult Men, with ER-positive...

                            Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.

                            Brand Name : Orserdu

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pirtobrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jaypirca™ (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Re...

                            Details : Jaypirca (pirtobrutinib) is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atria...

                            Brand Name : Jaypirca

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : Pirtobrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivosidenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Servier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TIBSOVO® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-Mutant Acute M...

                            Details : TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia (AML).

                            Brand Name : Tibsovo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : Ivosidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Servier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Myovant Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ORGOVYX® (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate Ca...

                            Details : ORGOVYX® (relugolix), which is a gonadotropin-releasing hormone (GnRH) antagonist that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer.

                            Brand Name : Orgovyx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Myovant Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : CTI BioPharma Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VONJO™ (pacritinib) Now Approved for the Treatment of Adults with Intermediate or High-Risk Primary or Secon...

                            Details : FDA’s approval of VONJO (pacritinib) is based upon results of PERSIST-2 clinical trial indicate that 29% of myelofibrosis patients with baseline platelet levels of less than 50 x 109/L obtained spleen volume reductions of at least 35% during first six ...

                            Brand Name : Vonjo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : CTI BioPharma Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            REZUROCK™ Tablets Approved to Treat Adult and Pediatric Patients 12 Years and Older With Chronic Graft-Versu...

                            Details : The FDA’s approval of REZUROCK comes as a result of the Phase II KD025-213 clinical trial which demonstrated 75% overall response rate after six cycles of therapy at a dose of 200mg orally once daily in patients with chronic GVHD disease.

                            Brand Name : Rezurock

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2021

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth